TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15688822

Group type: EXPERIMENTAL
Intervention: Adjuvant intraperitoneal chemotherapy with 50 mg of cisplatinum for washing the peritoneal cavity and 20 mg/m2 of cisplatinum intraperitoneally for the first four days after surgery.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard treatment (control group).
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Adjuvant intraperitoneal chemotherapy.
Number of subjects: 8
Study: 11738120

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) infusions
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Bivariate mixed‐effects model
Number of subjects: 4
Study: 9848527

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Access flap alone
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: GTR
Number of subjects: 143

Group type: COMPARATOR
Intervention: Access flap
Number of subjects: 143
Study: 7863464

Group type: EXPERIMENTAL
Intervention: Cloricromene (100mg gastroresistant capsules twice a day for 7 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 24
Study: 2792540

Group type: EXPERIMENTAL
Intervention: Aspiration catheter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tissue biopsy forceps
Number of subjects: 30
Study: 406300

Group type: EXPERIMENTAL
Intervention: Intranasal cromolyn sodium solution (4% solution, 5.2 mg into each nostril 6 times daily)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 66
Study: 31519202

Group type: EXPERIMENTAL
Intervention: ANCOVA method with assumed correlation of 0.50
Number of subjects: 7173

Group type: COMPARATOR
Intervention: Analysis of POST treatment means method
Number of subjects: 7173

Group type: EXPERIMENTAL
Intervention: CHANGE method
Number of subjects: 7173

Group type: EXPERIMENTAL
Intervention: Analysis of covariance (ANCOVA)
Number of subjects: 7173

Group type: EXPERIMENTAL
Intervention: Mean correlation between baseline and follow-up PROM assessments
Number of subjects: 7173
Study: 27196995

Group type: EXPERIMENTAL
Intervention: Umbilical Cord Serum (UCS)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Autologous Serum (AS)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Artificial Tears (AT)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: UCS and AS
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: AS and UCS
Number of subjects: 105
Study: 25648379

Group type: EXPERIMENTAL
Intervention: Nitrous oxide anesthesia (2 L/min nitrous oxide and 1 L/min oxygen)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nitrous oxide-free anesthesia (2 L/min air and 1 L/min oxygen)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Comparison of nitrous oxide vs nitrous oxide-free
Number of subjects: 59
Study: 24324084

Group type: EXPERIMENTAL
Intervention: ifosfamide-gemcitabine (IG)
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: gemcitabine, ifosfamide, cisplatin (GIP)
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin (DP)
Number of subjects: 693
Study: 21299294

Group type: EXPERIMENTAL
Intervention: Quit advice plus carbon‐monoxide level feedback
Number of subjects: 160

Group type: COMPARATOR
Intervention: Quit advice plus leaflet (control)
Number of subjects: 160
Study: 19659979

Group type: EXPERIMENTAL
Intervention: Thalidomide at a dose of 300 mg/day for 1 week, gradually reduced thereafter.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prednisolone 40 mg daily for 2 weeks, tapered by 10 mg every 2 weeks.
Number of subjects: 60
Study: 16952213

Group type: EXPERIMENTAL
Intervention: Milligan-Morgan haemorrhoidectomy
Number of subjects: 225

Group type: COMPARATOR
Intervention: Ferguson haemorrhoidectomy
Number of subjects: 225
Study: 15307695

Group type: EXPERIMENTAL
Intervention: Qilian decoction (QLD) given orally, one dose taken twice a day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (hypoglycemic agent in routine)
Number of subjects: 62
Study: 11780351

Group type: EXPERIMENTAL
Intervention: Extrinsic positive end-expiratory pressure (PEEPe) at varying levels (0%, 40%, 60%, 80%, 100% of PEEPi, dynz)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Extrinsic positive end-expiratory pressure (PEEPe) at 80% and 100% of PEEPi, dynz
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Extrinsic positive end-expiratory pressure (PEEPe)
Number of subjects: 10
Study: 9280714

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg/d)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg/d)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 mg/d)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8343915

Group type: EXPERIMENTAL
Intervention: 5% EMLA cream (25 mg/mL of lidocaine and prilocaine)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2883575

Group type: EXPERIMENTAL
Intervention: enalapril (2.5 to 40 mg per day)
Number of subjects: 253

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 253
Study: 31925970

Group type: EXPERIMENTAL
Intervention: Human disease network (HDN) analysis of disease treatment cost
Number of subjects: 1000000
Study: 31231923

Group type: COMPARATOR
Intervention: Topical capsaicin (Zostrix HP 0.075%) only (CAP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical capsaicin with preheating (CAP + HEAT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topical nonsensitizing placebo cream (CON)
Number of subjects: 20
Study: 28432757

Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 402

Group type: COMPARATOR
Intervention: Traditional consultation
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Telemedicine communication satisfaction
Number of subjects: 402
Study: 26323444

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX) digluconate and 0.05% cetylpyridinium chloride (CPC) solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 40
Study: 23518704

Group type: EXPERIMENTAL
Intervention: Drain antisepsis (chlorhexidine disc at drain exit site and irrigation with dilute sodium hypochlorite solution)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard drain care (twice daily cleansing with alcohol swabs)
Number of subjects: 100
Study: 21632472

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1342
Study: 19252449

Group type: EXPERIMENTAL
Intervention: Oral rehydration salt solutions containing rice
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral rehydration salt solutions containing amylase-resistant starch
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral rehydration salt solutions containing glucose
Number of subjects: 30
Study: 16682179

Group type: EXPERIMENTAL
Intervention: Adenosine (6mg bolus, max 12mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Verapamil (5mg bolus, max 10mg)
Number of subjects: 64
Study: 15186629

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (LGBP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Laparoscopic vertical banded gastroplasty (LVBG)
Number of subjects: 80
Study: 11565401

Group type: EXPERIMENTAL
Intervention: Intercessory prayer
Number of subjects: 95

Group type: COMPARATOR
Intervention: Positive visualization
Number of subjects: 95

Group type: COMPARATOR
Intervention: Expectancy
Number of subjects: 95
Study: 9450156

Group type: EXPERIMENTAL
Intervention: pivagabine, 900 mg/d for 90 days
Number of subjects: 186

Group type: COMPARATOR
Intervention: placebo for 90 days
Number of subjects: 186
Study: 7521828

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists
Number of subjects: 0
Study: 3345636

Group type: EXPERIMENTAL
Intervention: 5% bupivacaine aerosol
Number of subjects: 6

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline) aerosol
Number of subjects: 6
Study: 28671856

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg intravenously every 2 weeks
Number of subjects: 405

Group type: COMPARATOR
Intervention: Investigator's choice chemotherapy (ICC; dacarbazine 1,000 mg/m2 every 3 weeks or carboplatin AUC 6 plus paclitaxel 175 mg/m2 every 3 weeks)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Investigator's choice chemotherapy (ICC)
Number of subjects: 405
Study: 27392256

Group type: EXPERIMENTAL
Intervention: Internet program 'Lose It' (recording daily calories and physical activity)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Daily wellness program (health tips delivered via e-mail)
Number of subjects: 24
Study: 25179846

Group type: EXPERIMENTAL
Intervention: VITACORA-19 questionnaire
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: VITACORA-19 scores
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Minimum important difference
Number of subjects: 323
Study: 22520532

Group type: EXPERIMENTAL
Intervention: Intervention group received enhanced in‐hospital counseling, attention to adherence barriers, communication of discharge medications to community pharmacists and physicians, and ongoing assessment of adherence by community pharmacists.
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group received usual care with discharge counseling and a letter to the community physician.
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study: 20846085

Group type: EXPERIMENTAL
Intervention: Patient navigator providing social support
Number of subjects: 0
Study: 18632105

Group type: EXPERIMENTAL
Intervention: Methotrexate (30 mg/m2 intramuscularly weekly)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Actinomycin D (1.25 mg/m2 intravenous bolus every 2 weeks)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 131

Group type: COMPARATOR
Intervention: Actinomycin D
Number of subjects: 131
Study: 16837736

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 750 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1000 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1000 mg + Norethisterone enanthate (NETE) 200 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 12473978

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bethanecol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Biotene
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10081088

Group type: EXPERIMENTAL
Intervention: Ultrastructural analysis of specialized conducting and working myocytes in the sinoatrial region of the human heart
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ratio of light to dark myocytes in the sinus node
Number of subjects: 45
Study: 7982257

Group type: EXPERIMENTAL
Intervention: Uni-Dur (600 mg once daily for 5 doses)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Theo-Dur (300 mg twice daily for 10 doses)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Uni-Dur
Number of subjects: 18

Group type: COMPARATOR
Intervention: Theo-Dur
Number of subjects: 18
Study: 3276446

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG) in association with antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 0
Study: 31028421

Group type: EXPERIMENTAL
Intervention: Vaginal sacrospinous fixation with anterior mesh (VSF-AM)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Abdominal sacrocolpopexy (ASC)
Number of subjects: 71
Study: 31724353

Group type: EXPERIMENTAL
Intervention: SU Jia-fu's Wenjing Tongdu external treatment combined with long-snake moxibustion at the governor vessel, twice a week for 8 weeks.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Routine acupuncture and rehabilitation of bladder function (Control group).
Number of subjects: 64
Study: 27923432

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 166

Group type: COMPARATOR
Intervention: Alarms
Number of subjects: 166

Group type: COMPARATOR
Intervention: Room temperature
Number of subjects: 166

Group type: COMPARATOR
Intervention: Anxiety
Number of subjects: 166
Study: 23818201

Group type: EXPERIMENTAL
Intervention: Gastrosis No.1 compound (Chinese herbal medicine)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 21053054

Group type: EXPERIMENTAL
Intervention: Dental amalgam fillings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Composite fillings
Number of subjects: 0
Study: 19797813

Group type: EXPERIMENTAL
Intervention: Sago gel (SG)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sago porridge (SR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sago paste (SP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: White bread (WB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sago meals (SR, SP, SG)
Number of subjects: 12
Study: 17137743

Group type: EXPERIMENTAL
Intervention: Mortality graphs (15 years of data)
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: Mortality graphs (5 years of data)
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Survival graphs (15 years of data)
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Survival graphs (5 years of data)
Number of subjects: 1461
Study: 15137922

Group type: EXPERIMENTAL
Intervention: 3R,3'R-zeaxanthin dipalmitate (5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: non-esterified 3R,3'R-zeaxanthin (5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3R,3'R-zeaxanthin dipalmitate
Number of subjects: 12

Group type: COMPARATOR
Intervention: non-esterified 3R,3'R-zeaxanthin
Number of subjects: 12
Study: 11133608

Group type: EXPERIMENTAL
Intervention: Desflurane with routine antiemetic prophylaxis
Number of subjects: 0
Study: 9609607

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 400 microg bid
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 8093139

Group type: EXPERIMENTAL
Intervention: 10 mg fluvastatin
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: 20 mg fluvastatin
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: 10 mg fluvastatin plus 8 g cholestyramine
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: 20 mg fluvastatin plus 8 g cholestyramine
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: 16 g cholestyramine in combination groups
Number of subjects: 224
Study: 2804777

Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Hemorrhoidectomy
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal control
Number of subjects: 56
Study: 31879317

Group type: EXPERIMENTAL
Intervention: Structured chart review methodology by primary reviewers
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Structured chart review methodology by secondary reviewers
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Duplicate reviews
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Pathophysiological categories
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Therapeutic categories
Number of subjects: 327
Study: 27678010

Group type: EXPERIMENTAL
Intervention: Modern radiotherapy techniques and field designs as part of the quality assurance program (QAP) developed by the expert panel.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Quality assurance program (QAP) for modern radiotherapy (RT).
Number of subjects: 11
Study: 25975733

Group type: EXPERIMENTAL
Intervention: Basic bladder advice for 1 month followed by alarm therapy (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Alarm therapy only (group B)
Number of subjects: 40
Study: 23139373

Group type: EXPERIMENTAL
Intervention: Taspoglutide 10 mg weekly
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: Taspoglutide 20 mg weekly
Number of subjects: 1189

Group type: COMPARATOR
Intervention: Exenatide 10 µg twice daily
Number of subjects: 1189
Study: 20730547

Group type: EXPERIMENTAL
Intervention: Weight loss (average 12 lb, modal 19 lb)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss (10% decrease in baseline weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study: 19130937

Group type: EXPERIMENTAL
Intervention: SQ-standardized grass allergen tablet (Grazax)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study: 16469980

Group type: EXPERIMENTAL
Intervention: Butter high in vaccenic acid (3.6 g vaccenic acid/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control butter with low content of vaccenic acid
Number of subjects: 42
Study: 15909709

Group type: EXPERIMENTAL
Intervention: Uterine exteriorization during caesarean section
Number of subjects: 136
Study: 12792580

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 60
Study: 9928690

Group type: EXPERIMENTAL
Intervention: Addition of GP physicians in the ED
Number of subjects: 4694
Study: 7759830

Group type: COMPARATOR
Intervention: Piperacillin 4 g intravenously (group P)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Piperacillin 4 g with sulbactam 2 g intravenously (group SP)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Both groups (P and SP)
Number of subjects: 379
Study: 2216936

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 80579

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone (as second drug)
Number of subjects: 0
Study: 31805386

Group type: EXPERIMENTAL
Intervention: Coil-type anchor
Number of subjects: 40

Group type: COMPARATOR
Intervention: Screw-type anchor
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study: 31129442

Group type: EXPERIMENTAL
Intervention: Patients with ≥1 comorbidity (LVAD recipients)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Patients with pulmonary hypertension
Number of subjects: 239

Group type: COMPARATOR
Intervention: Patients without pulmonary hypertension
Number of subjects: 239

Group type: COMPARATOR
Intervention: Patients with chronic renal disease or high body mass index
Number of subjects: 239
Study: 28185713

Group type: EXPERIMENTAL
Intervention: High-dose pitavastatin (4 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-dose pitavastatin (2 mg/d)
Number of subjects: 60
Study: 24842590

Group type: EXPERIMENTAL
Intervention: Faces Intervention
Number of subjects: 71

Group type: COMPARATOR
Intervention: Stories Intervention
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control Intervention
Number of subjects: 71
Study: 23093223

Group type: EXPERIMENTAL
Intervention: D-serine (30 mg/kg) + CRT (5 h/week)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: D-serine + control CRT
Number of subjects: 104

Group type: COMPARATOR
Intervention: CRT + placebo D-serine
Number of subjects: 104

Group type: COMPARATOR
Intervention: placebo + control CRT
Number of subjects: 104
Study: 22118312

Group type: EXPERIMENTAL
Intervention: Topical cromolyn sodium 2% ophthalmic solution without 0.01% benzalkonium chloride (BAK)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Topical cromolyn sodium 2% ophthalmic solution with 0.01% benzalkonium chloride (BAK)
Number of subjects: 33
Study: 19189907

Group type: EXPERIMENTAL
Intervention: Nurse discharge advocate intervention with follow-up appointments, medication reconciliation, and patient education
Number of subjects: 749

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Nurse discharge advocate intervention
Number of subjects: 749
Study: 16917166

Group type: EXPERIMENTAL
Intervention: Group 3 performed exercises which all incorporated volitional, planned head rotations.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 4 performed exercises that involved translating the body and incorporated volitional, planned head motion.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group 1 viewed a video (control group).
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group 2 performed exercise that involved translating the entire body through space, but without separate, volitional head movement.
Number of subjects: 80
Study: 14676595

Group type: EXPERIMENTAL
Intervention: Formula supplemented with nucleotides (group F-NT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard milk formula without nucleotides (group F)
Number of subjects: 150
Study: 10674503

Group type: EXPERIMENTAL
Intervention: PCA fentanyl
Number of subjects: 23

Group type: COMPARATOR
Intervention: PCA alfentanil
Number of subjects: 23
Study: 9324189

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 47

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 47
Study: 8404943

Group type: EXPERIMENTAL
Intervention: Taprostene (6.25, 12.5, or 25.0 ng.kg‐1 x min‐1) infused for 48 hours followed by a 24-hour tapering period.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo infused for 48 hours followed by a 24-hour tapering period.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Taprostene (up to 25 ng.kg‐1 x min‐1)
Number of subjects: 80
Study: 3811811

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 30
Study: 31099402

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks + topical corticosteroids (TCS)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Cyclosporine + topical corticosteroids (TCS)
Number of subjects: 163
Study: 28481157

Group type: EXPERIMENTAL
Intervention: Risk information followed by gain-framed messages
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Risk information followed by loss-framed messages
Number of subjects: 237

Group type: COMPARATOR
Intervention: No risk information followed by gain-framed messages
Number of subjects: 237

Group type: COMPARATOR
Intervention: No risk information followed by loss-framed messages
Number of subjects: 237
Study: 25452300

Group type: EXPERIMENTAL
Intervention: Higher systolic BP target (130-149 mm Hg)
Number of subjects: 3020

Group type: COMPARATOR
Intervention: Lower systolic BP target (<130 mm Hg)
Number of subjects: 3020